CD274 and cancer: Noting that cancer patients may still possess resistance to anti-PD-L1 therapy despite expressing PD-L1 highlights the importance of other ICPs that can mediate immune evasion in distinct or complementary pathways, especially in the highly resistant CSC subpopulation [61–63].